$NGTF Nightfood Adds Sales Director to Grow Distribution

New Post Public Reply Private Reply Replies (0) Message Board
Lee Adams Lee Adams #71571
106
$NGTF Nightfood Adds Sales Director to Grow Distribution and Revenue in New and Existing Supermarket Chains Through Partnership with WeStock’s New “Radish” Service

Tarrytown, NY, Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nightfood, Inc. (OTCQB: NGTF), the award-winning ice cream company addressing America’s $50 billion-dollar nighttime snacking problem, announced today that they have partnered with WeStock’s new "Radish" service to add Jessie Trinchard as Nightfood’s Sales Director.

Radish is a shared Sales Director program introduced by TechStars alum company WeStock. The program provides growing brands a shared, industry leading sales director to oversee and coordinate national sales so they can reach $3M - $5M in revenues in a quick and affordable way, at which time they’d typically bring on a full-time sales director.

Nightfood has recently secured distribution in additional major supermarket chains which will be announced shortly, and Trinchard will work with these new accounts to help drive maximum awareness and sales velocity starting on day one.

Trinchard is an industry veteran with over a decade of experience in sales and marketing management positions in high-growth brands in the food and beverage sector. Her resume includes management and director experience in multiple national brands that have since been acquired for an aggregate of over $500 million dollars.

“Nightfood ice cream was one of our most highly requested brands on the WeStock crowdstocking platform, and now we’re taking our relationship to a higher level,” commented WeStock Co-Founder and CEO Cameron McCarthy. “I think Radish and Nightfood are a great fit together, and I’m excited to watch the coming months unfold.”

As Nightfood’s Sales Director, Trinchard will work with existing management to oversee broker and distributor relationships, coordinate consumer and trade promotions, and identify and develop new partnerships and sales opportunities.

“With new supermarket chains committed for early 2020, and major marketing initiatives in the works, it’s definitely time to add a national sales director,” commented Nightfood CEO Sean Folkson. “We expect these marketing programs to drive a significant, immediate, and sustainable increase in consumer pull and sales velocity upon launch. This should lead to more chains adding Nightfood here in 2020, in addition to the soon-to-be announced chains that have already committed. This is shaping up to be a very exciting quarter for all shareholders and we’re going to need all hands on deck. Jessie’s experience will be a huge asset throughout this national rollout.”

Trinchard added, “Rolling into major divisions of the largest supermarket chains in the country puts us in great position for rapid expansion. The statistics on unhealthy night snacking are overwhelming, and I believe we can benefit millions. I’m looking forward to helping Nightfood become a powerful national brand as I’ve done before.”

About Nightfood Holdings:

Nightfood Holdings, Inc. (OTC: NGTF), owns Nightfood, Inc. and MJ Munchies, Inc.

After manufacturing their first pint in early 2019, Nightfood secured ice cream distribution in multiple Top-10 supermarket chains in the United States, with concentrations in the Carolinas, Mid-Atlantic, the upper Midwest, and New England.

Management has also begun to focus on distribution of Nightfood sleep-friendly ice cream in hotels across the United States, and is currently available in certain locations of chains such as Fairfield Inn & Suites (Marriott), Hilton Garden Inn (Hilton), Staybridge Suites (InterContinental Hotels Group), and Residence Inn (Marriott).

On Feb 8, 2019, it was announced that Nightfood ice cream won the 2019 Product of the Year award in the ice cream category in a Kantar survey of over 40,000 consumers. On June 26, 2019, Nightfood was named Best New Ice Cream in the 2019 World Dairy Innovation Awards.

Over 80% of Americans snack regularly at night, resulting in an estimated 700M+ nighttime snack occasions weekly, and an annual spend on night snacks of over $50 billion dollars, the majority of it on options that are understood to be both unhealthy, and disruptive to sleep quality.

Scientific research indicates these unhealthy nighttime cravings are driven by human biology. Willpower is also weakest at night, contributing to unhealthy night snacking behavior, and the majority of night snackers report feeling both guilty and out-of-control when it comes to their nighttime snacking.

Because unhealthy night snacking is biologically driven, and not a trend or a fad, management believes the category of nighttime-specific nutrition, which Nightfood is pioneering, will be a billion-dollar category.

MJ Munchies, Inc. was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company is seeking licensing opportunities to market such products under the brand name “Half-Baked”, for which they’ve successfully secured trademark rights.

Questions can be directed to investors@Nightfood.com.

Forward Looking Statements:

This current press release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, any products sold or cash flow from operations.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with distribution and difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Media Contact:
Tim Sullivan
media@Nightfood.com
732-816-0239

Investor Contact:
Stuart Smith
investors@Nightfood.com
888-888-6444, x3
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 5

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 1

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 2

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

CAPREIT Welcomes Francine Moore to Board of Trustees

Updated Category News Views 162

CAPREIT Welcomes Francine Moore to Board of Trustees CAPREIT is excited to share that Ms. Francine Moore has been appointed as a new member of its Board of Trustees. This appointment took effect on November 7. Francine is known for her significant experience in the real estate sector, where she has built a remarkable career. Ms. Moore's Impressive Background With over 25...

Continue Reading
Cimpress Sees Target Adjustments Yet Remains Strong – A Deeper Look

Updated Category News Views 95

Cimpress Stock Target Adjustments and Outlook Recently, Truist Securities made notable adjustments to the stock price target for Cimpress N.V. (NASDAQ: CMPR), a recognized leader in mass customization solutions. The new target is now set at $110.00, reduced from the previous $120.00. Despite this adjustment, the firm has reiterated a Buy rating, showcasing confidence in...

Continue Reading
Significant Shift in NICUs: Embracing Prolacta's Innovations

Updated Category News Views 131

Transforming Neonatal Care with Prolacta's Nutritional Innovations Prolacta Offers the Only Nutritional Products Free From Cow Milk and Added Synthetic Ingredients for Extremely Premature Infants in the U.S. In an exciting development for neonatal care, Prolacta Bioscience® has reported that in 2025, the majority of Level III and IV neonatal intensive care units (NICUs)...

Continue Reading
Orchestry Unveils Automated Workspace Solutions for Microsoft 365

Updated Category News Views 127

Orchestry Launches Innovative Workspace Review for Teams and SharePoint Orchestry has introduced a groundbreaking feature that aims to transform the way IT administrators manage collaboration workspaces within Microsoft 365. This new capability, known as Workspace Review, not only automates the maintenance of these workspaces but also enhances security and compliance...

Continue Reading
The Investment Journey of Webster Financial Over Five Years

Updated Category News Views 151

Understanding Webster Financial's Growth Over the Years Webster Financial (NYSE: WBS) has demonstrated remarkable performance in the stock market, consistently outperforming many competitors. Over the past five years, it has achieved an impressive average annual return of 15.04%, surpassing the market by 1.25% annually. This impressive growth reflects the ongoing...

Continue Reading